Therapy Areas: Autoimmune
Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb7195 for the Development of Next-Generation Food Allergy Treatments
11 February 2020 - - US-based clinical-stage biopharmaceutical company Xencor, Inc. (NASDAQ: XNCR) has granted an exclusive worldwide license to develop and commercialise the investigational humanised monoclonal antibody XmAb7195 to Aimmune Therapeutics, Inc, the company said.

XmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma.

It uses three distinct mechanisms of action to reduce blood serum IgE and suppress IgE-producing cells.

Aimmune initially plans to develop AIMab7195 as an adjunctive treatment with select Characterized Oral Desensitized ImmunoTherapy (CODIT) programmes, including Palforzia, to explore treatment outcomes in patients with food allergies.

Under the terms of the agreement, Aimmune will make an upfront payment to Xencor of USD 5m in cash and USD 5m in equity, equivalent to 156,238 newly issued shares of Aimmune common stock at USD 32.00/share, the seven-day volume weighted average price.

Xencor also is eligible to receive up to USD 385m based on the achievement of certain clinical development, regulatory and commercialisation milestones beginning with the initiation of a Phase 2 clinical trial and is eligible to receive a high single-digit to mid-teen percentage of royalties upon commercialisation of AIMab7195.

Aimmune will be solely responsible for costs related to the development of AIMab7195 and plans to provide a development plan in the coming months.

AIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcγRIIb).

IgE recognises and interacts with allergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response in patients.

AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from interacting with its receptor on immune cells.

AIMab7195 has been evaluated in two Phase 1 studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.

Currently, 15 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.

Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

AIMab7195, PALFORZIA, AIMMUNE, AIMMUNE THERAPEUTICS and CODIT are trademarks of Aimmune Therapeutics, Inc

Xencor and XmAb are registered trademarks of Xencor, Inc.